Pharmacological or genetic perturbation of MAP4 recapitulated the synthetic lethality phenotype in ARID1A-deficient cells, further supporting the idea that MAP4 is a key microtubule dynamics regulator in ARID1A-deficient CRC, and it could serve as a therapeutic target. The gene discussed is MAP4; the disease is colorectal carcinoma.